VOLITIONRX LTD

VNRXSEC EDGAR

In Vitro & In Vivo Diagnostic Substances(DE)CIK: 93314

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenues	$775.3K	$306.4K	$90.0K	$13.4K	$17.1K
Research and Development Expense	$19.6M	$15.3M	$13.0M	$14.5M	$10.4M
Operating Expenses	$36.8M	$32.1M	$28.4M	$21.3M	$16.1M
Operating Income (Loss)	-$36.0M	-$31.8M	-$28.3M	-$21.2M	-$16.0M
Interest Expense	—	—	—	$129.8K	$126.6K
Nonoperating Income (Expense)	—	$1.2M	—	$848.5K	-$56.1K
Income Tax Expense (Benefit)	—	—	—	—	—

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$28.0M	$18.3M	$27.5M	$26.2M	$21.3M
Assets, Current	$21.9M	$12.2M	$22.0M	$20.3M	$17.6M
Cash and Cash Equivalents, at Carrying Value	$20.7M	$10.9M	$20.6M	$17.0M	$13.4M
Accounts Receivable, after Allowance for Credit Loss, Current	$242.6K	$72.6K	$12.5K	$7.1K	$0.00
Liabilities	$36.7M	$21.4M	$9.8M	$9.9M	$7.1M
Liabilities, Current	$8.9M	$17.4M	$6.5M	$6.2M	$3.9M
Long-term Debt	$4.8M	$4.8M	$3.8M	$3.1M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$18.1M	-$15.3M	-$20.9M	-$16.5M	-$12.7M
Net Cash Provided by (Used in) Investing Activities	-$1.1M	-$1.6M	-$973.6K	-$1.6M	-$511.3K
Net Cash Provided by (Used in) Financing Activities	$29.0M	$6.9M	$22.9M	$20.6M	$16.9M
Payments to Acquire Property, Plant, and Equipment	$1.1M	$1.6M	$973.6K	$1.9M	$511.3K
Payments for Repurchase of Common Stock	$31.8K	$0.00	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)